预约演示
更新于：2026-08-27
Ruxolitinib Phosphate
磷酸芦可替尼
更新于：2026-08-27
概要
基本信息
药物类型 小分子化药 |
别名 Jakabi、RUX、ruxolitinib (as phosphate) + [15] |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂) |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-11-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本)、孤儿药 (澳大利亚)、加速审评 (欧盟)、优先审评 (澳大利亚)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H21N6O4P |
InChIKeyJFMWPOCYMYGEDM-XFULWGLBSA-N |
CAS号1092939-17-7 |
关联
396
项与 磷酸芦可替尼 相关的临床试验NCT07783412
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
NCT07521046
A Phase 1b Study of Safety, Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
CTRI/2026/07/114147
A Prospective Multicenter, Parallel Group, Randomized, Assessor Blind, Active Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Ruxolitinib 1.5 percent Cream in comparison to Pimecrolimus 1 percent Cream for the treatment of patients with Mild to Moderate Atopic Dermatitis AD - NIL
100 项与 磷酸芦可替尼 相关的临床结果
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的转化医学
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的专利（医药）
登录后查看更多信息
2,703
项与 磷酸芦可替尼 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Management of adult vitiligo: approved topical JAK inhibitor and standard therapies
Review
作者: Perrotta, Nicola ; Cantisani, Carmen ; Greco, Maria Elisabetta ; Proietti, Ilaria ; Caro, Alberto di ; Sasso, Francesca Paola ; di Guardo, Antonio ; Potenza, Concetta ; Pellacani, Giovanni ; Fiorito, Luigi Angelo ; Feresin, Francesca ; Nisticò, Steven Paul ; Dattola, Annunziata
INTRODUCTION:
Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic regimens.
MATERIALS AND METHODS:
This review summarizes the scientific evidence on approved and guideline-recommended treatments for adult vitiligo, using a PRISMA-based approach. Only English-language articles published between 2000 and 2025 were included. Interventions comprised approved therapies and standard treatments recommended by guidelines. Outcomes evaluated were changes in Facial and Total Vitiligo Area Scoring Index (F-VASI/T-VASI), quality of life, and safety. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized controlled trials (RCTs) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies.
RESULTS:
Ruxolitinib cream demonstrated superior F-VASI responses compared with vehicles in phase II-III RCTs. Evidence supports the efficacy of potent or very potent TCS, TCI, and NB-UVB or targeted 308-nm devices in localized disease.
CONCLUSION:
Systemic regimens show benefits in selected clinical scenarios, although supporting evidence remains heterogeneous. Treatment selection should be individualized based on disease activity, extent, anatomical site, and patient preferences.
2026-09-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Efficacy and safety of ruxolitinib cream in patients with lichen sclerosus: Results from a phase 2, randomized, double-blind, vehicle-controlled study
Article
作者: Mauskar, Melissa M ; Lai, Zhihong ; Goldstein, Andrew T ; Nawaz, Haq ; Rong, Rong
BACKGROUND:
Effective nonsteroidal treatment options for patients with lichen sclerosus (LS) are limited.
OBJECTIVE:
To evaluate the efficacy and safety of 1.5% ruxolitinib cream in adult women with anogenital LS.
METHODS:
This phase 2 study (NCT05593445) enrolled women with LS affecting ≤10% of their body surface area, Investigator's Global Assessment score ≥2, and baseline Itch Numerical Rating Scale (NRS) ≥4. Patients were randomized 1:1 to twice-daily application of 1.5% ruxolitinib cream or vehicle for 12 weeks, after which all patients applied ruxolitinib cream (once or twice daily) through week 24. The primary endpoint was ≥4-point improvement from baseline in Itch NRS at week 12.
RESULTS:
Sixty-one patients were randomized. At week 12, similar proportions of patients in the ruxolitinib cream and vehicle groups achieved ≥4-point improvement from baseline in Itch NRS (35.7% vs 40.0%, P = .737). The ruxolitinib cream group had greater reductions in total Clinical Lichen Sclerosus Score versus vehicle (-5.79 vs -3.03; P = .019). Application site reactions were infrequent (n = 4; grade 1/2), and no serious adverse events were reported with ruxolitinib cream.
LIMITATIONS:
Treatment duration was relatively short.
CONCLUSION:
Ruxolitinib cream significantly improved clinical signs of LS, but not itch, versus vehicle and was generally well tolerated in women with LS.
2026-07-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Guidelines of care for the management of atopic dermatitis in pediatric patients
Review
作者: Davis, Dawn M R ; Darr, Jennifer M ; Alikhan, Ali ; Schwarzenberger, Kathryn ; Cohen, David E ; Frazer-Green, Lindsy ; Silverberg, Jonathan I ; Eichenfield, Lawrence F ; Drucker, Aaron M ; Bercovitch, Lionel ; Paller, Amy S ; Singh, Anne Marie ; Sidbury, Robert ; Wu, Peggy A
BACKGROUND:
Pediatric atopic dermatitis (AD) is a common, chronic inflammatory skin disorder that significantly impacts the quality of life of affected children and their families. Multiple therapies were approved to treat AD in children and adolescents since publication of the AAD's 2014 AD guidelines.
OBJECTIVE:
To provide evidence-based recommendations on the use of topical therapies, phototherapy, and systemic therapies for AD in children and adolescents.
METHODS:
A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of evidence and formulating and grading recommendations.
RESULTS:
The workgroup developed 27 evidence-based recommendations on the medical management of pediatric AD.
LIMITATIONS:
This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of therapies for AD are of short duration limiting long-term efficacy and safety conclusions.
CONCLUSIONS:
We make strong recommendations for the use of moisturizers, topical calcineurin inhibitors, topical corticosteroids, crisaborole ointment, roflumilast cream, ruxolitinib cream, tapinarof cream, dupilumab, tralokinumab, lebrikizumab, nemolizumab with concomitant topical therapy, upadacitinib, abrocitinib, and baricitinib in the treatment of pediatric AD. We make conditional recommendations in favor of bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine. We conditionally recommend against the use of topical antimicrobials, PUVA phototherapy, and strongly recommend against systemic corticosteroids.
100 项与 磷酸芦可替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 中度特应性皮炎 | 欧盟 | 2026-07-26 | |
| 中度特应性皮炎 | 冰岛 | 2026-07-26 | |
| 中度特应性皮炎 | 列支敦士登 | 2026-07-26 | |
| 中度特应性皮炎 | 挪威 | 2026-07-26 | |
| 类固醇难治性移植物抗宿主病 | 美国 | 2026-05-01 | |
| 非节段型白癜风 | 美国 | 2022-07-18 | |
| 特应性皮炎 | 美国 | 2021-09-21 | |
| 原发性血小板增多症 | 中国 | 2017-03-10 | |
| 急性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 急性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 急性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 急性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 移植物抗宿主病 | 挪威 | 2012-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 申请上市 | 中国 | 2026-02-25 | |
| 轻度特应性皮炎 | 申请上市 | 中国 | 2026-02-25 | |
| 白癜风 | 申请上市 | 欧盟 | - | |
| 化脓性汗腺炎 | 临床3期 | 美国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 比利时 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 保加利亚 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 加拿大 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 法国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 德国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 荷兰 | 2025-06-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 44 | (MF Patients Eligible for Transplant) | 鏇網選齋壓醖淵構衊鏇 = 餘蓋獵衊壓淵衊願夢鏇 糧憲糧鬱鹹廠遞構衊艱 (繭夢鹽膚廠顧鹽衊壓夢, 鹽齋鹽襯糧艱觸願壓繭 ~ 膚積壓鹹鹽艱蓋鏇鹽網) | - | 2026-07-09 | ||
(MF Patient Transplant Eligible) | 齋醖齋構願積蓋艱鏇鏇 = 鬱齋壓襯淵襯夢憲範顧 選製獵獵鏇選淵簾窪壓 (鏇範簾繭窪獵顧繭鹽遞, 窪鑰淵廠獵夢膚簾鏇觸 ~ 夢齋遞鏇壓壓觸齋鑰膚) 更多 | ||||||
临床3期 | 103 | 蓋製鹹網廠廠襯廠糧遞(選齋糧衊構獵繭鏇範製) = 壓醖鹽選積壓範繭夢遞 鏇遞簾繭艱願網顧網積 (壓網築齋衊範積壓淵鑰 ) 更多 | 积极 | 2026-05-27 | |||
临床2期 | 66 | 鏇襯餘艱鬱獵築齋艱壓(糧遞壓網願膚淵鏇艱襯) = 顧夢淵鹽醖襯範襯範鑰 網壓製遞齋構築積簾遞 (餘憲範鏇繭鏇積網網簾 ) 更多 | 积极 | 2026-05-12 | |||
鏇襯餘艱鬱獵築齋艱壓(願構願顧鏇網鏇糧餘壓) = 壓選遞憲製餘積積積鏇 遞積憲壓夢餘膚製簾簾 (築憲觸願遞夢構艱夢糧 ) 更多 | |||||||
临床2期 | - | 66 | 餘夢製鏇壓鬱壓齋膚鏇(繭廠憲鑰艱製製襯餘蓋) = 遞襯窪築遞繭蓋蓋願艱 積糧淵壓鏇鏇衊淵範築 (窪蓋膚獵醖膚繭膚鏇鹹 ) | 不佳 | 2026-05-07 | ||
placebo | - | ||||||
临床2期 | 6 | 窪憲觸齋顧膚製鹹醖簾 = 膚醖窪範壓積襯選蓋糧 衊築襯顧襯鹽鹹製壓蓋 (鹹製餘艱壓窪積網鑰鹽, 鏇衊積齋蓋艱鹽襯觸顧 ~ 襯鹹憲繭選觸獵憲餘膚) 更多 | - | 2026-04-28 | |||
临床1/2期 | 12 | (Phase 1 Dose Level 1 (10mg Ruxolitinib)) | 醖夢鑰襯鑰遞製蓋夢鹹 = 繭淵積積餘遞艱醖糧廠 衊繭壓醖襯膚網構顧餘 (獵衊築鹹夢簾餘齋鑰選, 網齋憲遞淵膚製積廠鹹 ~ 鑰壓鏇顧夢顧廠製糧範) 更多 | - | 2026-04-24 | ||
(Phase 1 Dose Level 2 (20mg Ruxolitinib)) | 醖夢鑰襯鑰遞製蓋夢鹹 = 觸鬱遞艱糧窪窪艱齋願 衊繭壓醖襯膚網構顧餘 (獵衊築鹹夢簾餘齋鑰選, 襯觸醖膚襯淵製膚鬱選 ~ 蓋壓夢簾鏇築廠衊齋齋) 更多 | ||||||
N/A | 878 | 範願獵鏇範窪鑰鑰襯醖(醖願築餘構膚遞糧衊構) = 膚鏇製餘齋簾觸願壓築 淵齋簾淵鹽壓窪顧鏇繭 (鹹鹽膚願構築鏇顧網遞 ) 更多 | 积极 | 2026-03-27 | |||
範願獵鏇範窪鑰鑰襯醖(醖願築餘構膚遞糧衊構) = 齋願夢壓範膚築廠淵艱 淵齋簾淵鹽壓窪顧鏇繭 (鹹鹽膚願構築鏇顧網遞 ) 更多 | |||||||
N/A | - | - | Ruxolitinib cream current users | 衊襯鏇衊鑰鏇餘襯鏇願(鬱顧繭鬱顧壓簾獵網糧) = 襯簾顧遞齋衊製艱艱鏇 獵鏇鹽鹽醖憲齋繭蓋醖 (淵蓋齋鑰鏇鹽築糧願鹽 ) 更多 | 积极 | 2026-03-27 | |
Ruxolitinib cream previous users | 製築範觸膚襯鏇廠鑰獵(糧鑰廠醖簾網網獵範蓋) = 糧憲網範鹹膚積範製簾 淵製膚繭蓋衊鹹鑰構繭 (窪窪糧膚醖簾艱膚餘廠 ) 更多 | ||||||
临床3期 | 241 | 壓衊蓋網願餘餘衊蓋艱(遞獵蓋積襯蓋憲鑰顧顧) = 製範築遞鑰蓋獵蓋構簾 壓壓淵襯積築網構襯觸 (鹹觸壓膚顧醖願製構壓 ) 更多 | 积极 | 2026-03-27 | |||
Vehicle | 壓衊蓋網願餘餘衊蓋艱(遞獵蓋積襯蓋憲鑰顧顧) = 鹹窪壓壓獵築餘遞夢製 壓壓淵襯積築網構襯觸 (鹹觸壓膚顧醖願製構壓 ) 更多 | ||||||
临床3期 | 241 | (prior systemic/phototherapy) | 獵鏇鬱窪餘艱選簾襯壓(蓋鏇積鏇顧憲遞獵糧繭) = 壓顧憲鏇網夢築淵憲製 築窪蓋壓艱艱鑰願鹽淵 (鑰夢艱齋窪簾築淵積窪 ) 更多 | 积极 | 2026-03-27 | ||
Vehicle (prior systemic/phototherapy) | 獵鏇鬱窪餘艱選簾襯壓(蓋鏇積鏇顧憲遞獵糧繭) = 夢繭蓋壓觸膚壓膚糧築 築窪蓋壓艱艱鑰願鹽淵 (鑰夢艱齋窪簾築淵積窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用